Related references
Note: Only part of the references are listed.Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study
Laura K. Ferris et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2020)
Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis
N. Van den Berghe et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial)
Joel M. Gelfand et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS)
D. Thaci et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies
N. D. Loft et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis A Randomized Clinical Trial
Selma Atalay et al.
JAMA DERMATOLOGY (2020)
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis A Phase 3 Randomized Clinical Trial
Andrew Blauvelt et al.
JAMA DERMATOLOGY (2020)
Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases A Systematic Review and Meta-analysis
Shamarke Esse et al.
JAMA DERMATOLOGY (2020)
A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate‐to‐severe plaque psoriasis
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study
Carle Paul et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
Mamitaro Ohtsuki et al.
JOURNAL OF DERMATOLOGY (2019)
Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study
Min-Geol Lee et al.
JOURNAL OF DERMATOLOGY (2019)
Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial
Tadashi Terui et al.
JAMA DERMATOLOGY (2019)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
B. E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and safety of biologics targeting interleukin-6,-12/23 and-17 pathways for peripheral psoriatic arthritis: a network meta-analysis
Dongze Wu et al.
RHEUMATOLOGY (2018)
Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects
Sauzanne Khalilieh et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2018)
Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study
O. Nemoto et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
Mamitaro Ohtsuki et al.
JOURNAL OF DERMATOLOGY (2018)
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
Mark G. Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis A Randomized Clinical Trial
Tadashi Terui et al.
JAMA DERMATOLOGY (2018)
EFFICACY AND SAFETY RESULTS OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 56 WEEKS FROM A PHASE 2A, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
A. Deodhar et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich et al.
LANCET (2017)
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study
H. Saeki et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases
George E. Fragoulis et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis
Yanli Zhuang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice
L. Leon et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2016)
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
R. G. Langley et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
K. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions
Dhavalkumar D. Patel et al.
IMMUNITY (2015)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Diamant Thaci et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
Ian Landells et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Clinical improvement in psoriasis with specific targeting of interleukin-23
Tamara Kopp et al.
NATURE (2015)
Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug
Charlie Schmidt
NATURE BIOTECHNOLOGY (2015)
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Kenneth B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial
Arthur Kavanaugh et al.
ARTHRITIS CARE & RESEARCH (2015)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
Howard Sofen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Comparison of the Pharmacokinetics of Subcutaneous Ustekinumab between Chinese and Non-Chinese Healthy Male Subjects across Two Phase 1 Studies
Yaowei Zhu et al.
CLINICAL DRUG INVESTIGATION (2013)
The complexity of adverse side-effects to biological agents
Francois Aubin et al.
JOURNAL OF CROHNS & COLITIS (2013)
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
A. B. Kimball et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes et al.
LANCET (2013)
Long-term efficacy of ustekinumab in moderate-to-severe psoriasis
A. B. Kimball et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
Atsuyuki Igarashi et al.
JOURNAL OF DERMATOLOGY (2012)
A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis
Kenneth B. Gordon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
B. E. Strober et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Yihua Cai et al.
IMMUNITY (2011)
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)
Tsen-Fang Tsai et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2011)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Induction of IL-17+ T cell trafficking and development by IFN-γ:: Mechanism and pathological relevance in psoriasis
Ilona Kryczek et al.
JOURNAL OF IMMUNOLOGY (2008)
IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage
Gretta L. Stritesky et al.
JOURNAL OF IMMUNOLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
Gerald G. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis
Jason R. Chan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
IL-23 promotes tumour incidence and growth
John L. Langowski et al.
NATURE (2006)
Understanding the IL-23-IL-17 immune pathway
BS McKenzie et al.
TRENDS IN IMMUNOLOGY (2006)
Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis
AD Hauer et al.
CIRCULATION (2005)
Share Paper
